Implementation of the NHS England Lung Cancer Screening Programme over 5 years.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Lung cancer screening with low-dose computed tomography has been proven to reduce lung-cancer-specific and all-cause mortality. The UK launched the NHS England Targeted Lung Health Check Programme in 2019, which has now become the national Lung Cancer Screening Programme, with full coverage expected by 2030. Here we present the progress and outcomes of the program. People aged 55-74 were offered low-dose computed tomography of the thorax if they had ever smoked and if risk thresholds, as determined by multivariable models, were met. Delivery of the program is through regionally federated clinical infrastructure and leadership, with national strategic, clinical and economic frameworks. The program has invited over two million people, with 7,193 lung cancers diagnosed-63.1% at tumor, node, metastasis stage 1 and 12.6% stage 2-to March 2025. This has increased the early-stage proportion of lung cancer in England over 5 years, particularly in socioeconomically deprived regions. The NHS England Programme exemplifies how large-scale implementation can be achieved at speed through centralized protocols and effective project management. The program has demonstrated feasibility and scalability in reaching high-risk and underserved populations, but needs to further address inequalities in participation. These findings support adoption of lung cancer screening across the UK and globally, and offer practical tools for international adaptation.
Description
Acknowledgements: We thank the extensive efforts by local site clinical and operational leads, the Midlands and Lancashire Care Commissioning Support Unit, Ipsos UK, NHS England analysts and cancer program team, expert advisory group and wider NHS England Leadership and cancer program team, and patient and public representation, which aided program funding, design, implementation and delivery, oversight, and data curation and analysis. This paper represents independent research supported by (1) the Royal Marsden Cancer Charity and (2) the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors received no specific funding for this work.
Keywords
Journal Title
Conference Name
Journal ISSN
1546-170X

